Arthrosi to Present Multiple Studies at EULAR Congress 2024

Arthrosi Therapeutics, Inc., a biotechnology firm based in San Diego, is making significant strides in the treatment of gout. The company, which specializes in the development of advanced URAT1 inhibitors, has announced the acceptance of two presentations at the upcoming European League Against Rheumatism (EULAR) Congress 2024. This prestigious event will take place in Vienna, Austria, from June 12 to June 15, 2024.

One of the highlights of the Congress will be the presentation of findings related to AR882, a novel and highly selective URAT1 inhibitor developed by Arthrosi Therapeutics. The data, derived from a 12-month global trial, will be showcased in a session titled "Clinical Poster Tours: Gout treatment in 2024." This study utilized digital caliper measurements and dual-energy computed tomography to demonstrate that AR882 significantly reduces tophi in patients suffering from chronic gouty arthritis. Dr. Robert Keenan, the Chief Medical Officer of Arthrosi Therapeutics, will present these findings on June 14 from 9:30 am to 10:30 am CEST.

Another significant presentation at the Congress will focus on the drug-drug interaction profile of AR882. The study reveals that AR882 does not interact with key renal, hepatic, and gastrointestinal transporters, an important consideration in the comprehensive management of patients with gout. This presentation, led by Litain Yeh, Ph.D., Co-Founder and CEO of Arthrosi Therapeutics, will also take place on June 14 during the same time slot.

Gout is a form of inflammatory arthritis characterized by high levels of uric acid in the blood, leading to the formation of uric acid crystals in the joints and soft tissues. This condition affects an estimated 13 million people in the United States, with symptoms including painful flare-ups, decreased mobility, and reduced quality of life. The kidneys play a crucial role in managing uric acid levels, but in over 90% of gout patients, insufficient uric acid excretion leads to elevated serum urate (sUA) levels and subsequent crystal deposition.

Arthrosi Therapeutics is at the forefront of addressing this medical challenge. Their lead product, AR882, has shown remarkable efficacy and safety in Phase 2 clinical trials, with significant results in the resolution of tophi, a severe manifestation of gout. The company aims to initiate a pivotal Phase 3 program in early 2024, which could further solidify AR882's potential as a best-in-class treatment for gout.

In summary, the upcoming EULAR Congress will provide a platform for Arthrosi Therapeutics to present critical data on AR882, underscoring its potential to transform the treatment landscape for gout patients. With millions affected by this debilitating condition, the developments from Arthrosi Therapeutics offer hope for more effective and targeted therapies in the near future.